Achieve Life Science

49 articles with Achieve Life Science

• Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020

  10/27/2020

  Achieve Life Sciences, Inc. announced the Company will host a Key Opinion Leader virtual roundtable event on cytisinicline and smoking cessation on Tuesday, November 17th, 2020, at 12:00PM EST.

• Achieve Life Sciences Announces to Present at the MicroCap Best Ideas Conference, October 13, 2020

  10/8/2020

  Achieve Life Sciences, Inc. announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually October 13th - 16th, 2020.

• Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

  10/7/2020

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced initiation of the Phase 3 ORCA-2 clinical trial.

• Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering

  8/4/2020

   Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 476,187 shares of its common stock at a price to the

• Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

  7/28/2020

  Achieve Life Sciences, Inc. announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020.

• Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program

  5/14/2020

  Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2020 financial results and provided an update on the cytisinicline clinical

• Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020

  5/5/2020

  Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its first quarter 2020 financial results on Thursday, May 14, 2020. Compa

• Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program

  11/6/2019

  Achieve Life Sciences, Inc. provided an update on the cytisinicline clinical development program and announced third quarter 2019 financial results.

• Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019

  10/31/2019

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019.

• Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study

  9/30/2019

  Achieve Life Sciences, Inc. announced completion of their maximum tolerated dose study.

• Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

  9/13/2019

  Achieve Life Sciences, Inc. announced that two presentations featuring final data from the Phase 2b ORCA-1 trial will be conducted at the SRNT-E Annual Conference on Friday, September 13th in Oslo.

• Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial

  9/5/2019

  Achieve Life Sciences, Inc. announced the Company will host its first investor day on Friday, September 20, 2019 in New York City.

• Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences

  9/4/2019

  Achieve Life Sciences, Inc. announced that John Bencich, Chief Financial and Operating Officer, will present at two upcoming investor conferences.

• /C O R R E C T I O N -- Achieve Life Sciences, Inc./

  8/8/2019

  Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update

• Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update

  8/8/2019

  Achieve Life Sciences, Inc. provided an update on the cytisinicline clinical development program and announced second quarter 2019 financial results.

• Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019

  7/30/2019

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, announced that it will report its second quarter 2019 financial results on Thursday, August 8, 2019.

• Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation

  7/23/2019

  Achieve Life Sciences, Inc. announced it has extended its strategic collaboration with the National Center for Complementary and Integrative Health at the National Institutes of Health.

• Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

  6/21/2019

  Achieve Life Sciences, Inc. announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted for oral presentation at the SRNT-E Annual Conference, to be held in Oslo, September 12-14, 2019.

• Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial

  6/11/2019

  3.0 mg, 3 times daily selected as dose for future clinical development

• Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline

  5/30/2019

  Achieve Life Sciences, Inc. announced that the United States Patent and Trademark Office has granted Achieve a patent on succinate salt of cytisinicline and use thereof.